Effectiveness and Tolerability of Nifedipine GITS in Patients with Chronic Kidney Disease and Uncontrolled Hypertension: A Prospective, Multicenter, Observational Study (ADRENAL)

• DOI: 10.1007/s12325-021-01850-3
• Publication Date: 2021-08-10T15:58:34Z
• Authors: Rong Lv; Jianghua Chen; Huamin Wang; Jijun Wang; Hong Cheng; Rong Li; Wei Li; Tao Zhang; Lixin Wei; Qinkai Chen; Jian Huang; Feng Yu; Shizhong Shen; Henglan Wu; Cuihong Liu; Fuyuan Hong; Jie Liu; Xiaoru Zhang; Hua Xiao; Wenbin Song
• Keywords: Tolerability; Clinical endpoint

Achieving target blood pressure (BP) goals in patients with chronic kidney disease (CKD) and uncontrolled hypertension is a challenge. Various studies have shown the efficacy of nifedipine gastrointestinal therapeutic system (GITS) 60 mg hypertension. However, there paucity clinical CKD. Hence, we conducted this study to evaluate effectiveness tolerability GITS Chinese CKD real-world settings. In prospective, multicenter, observational study, were given primary endpoint change office systolic BP (SBP) at 12 weeks. The secondary endpoints included changes weeks diastolic (DBP), SBP DBP subgroups (140–160 mmHg ≥ 160 mmHg) stages subgroups, control rate, adverse events (AEs). Statistical analysis was performed using SAS® version 9.4. total, 871 622 safety set respectively. mean baseline 162.9 97.3 mmHg, At week 12, − 24.0 (95% confidence interval [CI] 25.32, 22.65 mmHg); after missing data accounted for, it 23.9 CI 25.25, 22.60 mmHg). Marked decreases DBP, as well observed 12. rate 50.0%. Twenty-three (2.6%) reported least one drug-related AEs. No event hypotension or death occurred during study. Nifedipine showed reducing ClinicalTrials.gov identifier NCT03194633.